Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 798 results for "Ibrutinib"

IMBRUVICA® (ibrutinib) Approved with Conditions for Relapsed ...

Oral, once-daily, single-agent therapy fills an unmet need for new treatment options to help Canadians in the fight against this deadly disease TORONTO, July 30, 2015 /CNW/ - Janssen Inc. announced today that Health Canada has issued a Notice of ... Canada NewsWire, 1 day ago
[x]  
Pharmaceutical Business Review

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie (NYSE: ABBV) announced the European Commission (EC) granted marketing authorization for IMBRUVICA ® (ibrutinib) as the first treatment option available in all 28 member states of the European Union (EU) for the treatment of ...
 News-Medical.Net2 weeks ago Imbruvica cleared in Europe for Waldenstrom's macroglobulinemia  Seeking Alpha3 weeks ago Europe clears AbbVie's Imbruvica for Waldenstrom's macroglobulinaemia  FirstWord Pharma3 weeks ago IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe  Crawford Financial Planning3 weeks ago
[x]  

AbbVie's Imbruvica obtains European approval to treat blood cancer WM

AbbVie has received marketing approval from the European Commission (EC) for its Imbruvica (ibrutinib) to treat patients with Waldenstrom's macroglobulinemia (WM), a rare and slow-growing blood cancer. Approval was granted for the drug to treat WM ...
 Pharmaceutical Technology2 weeks ago

Janssens IMBRUVICA®▼(Ibrutinib) erhält zusätzliche Zulassung der EU-Kommission für die Behandlung von Waldenströms Makroglobulinämie

Janssen's IMBRUVICA ® ▼(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia Ibrutinib now the first EC-approved treatment option available for this rare B-cell lymphoma ...
 PR Newswire2 weeks ago
Pharmafile

European Imbruvica approval for Janssen

Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with a rare blood cancer. The European Commission (EC) approvedImbruvica (ibrutinib) for Waldenström's ...
 Pharmafile1 week ago IMBRUVICA (ibrutinib) receives additional European Commission approval for the treatment of Waldenström's Macroglobulinemia  Medical News Today1 week ago Ibrutinib recieves additional European Commission approval for the treatment of Waldenström's Macroglobulinemia  Ecancer Medicalscience2 weeks ago Janssen's ibrutinib approved by the EC for the treatment of Waldenström's macroglobulinemia  CPhI.cn2 weeks ago
[x]  

CORRECTION - Janssen-Cilag International NV: Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European..

/PRNewswire/ -- We would like to advise journalists and other readers that the news release "Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia" issued on 10 ...
 ADVFN India3 weeks ago
[x]  

TG Therapeutics announces encouraging results from Phase II CLL study

TG-1101 also appeared to abrogate ibrutinib related lymphocytosis with patients experiencing a median 75% reduction in their absolute lymphocyte count (ALC) by the end of month 3 following initiation of combination therapy and 70% of patients ...
 Individual.com3 weeks ago TG Therapeutics reports encouraging data from Phase I B-cell lymphoma studies  Individual.com1 month ago Infinity reports encouraging preclinical data from hematologic malignancy study  Individual.com1 month ago

Ibrutinib shows promise in CLL/SLL

medwireNews: The addition of ibrutinib to bendamustine and rituximab significantly prolongs progression-free survival (PFS) in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), according to the HELIOS trial. The ...
 MedWire News1 month ago

Ibrutinib (IMBRUVICA®▼) HELIOS-Daten aus einer Zwischenanalyse zeigen eine deutliche Reduzierung des Risikos der Progression oder des Todes bei Patienten mit zuvor behandelter chronischer lymphozytischer Leukämie

BEERSE, Belgien, June 1, 2015 /PRNewswire/ -- Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR Newswire als besonderer Service für seine Kunden angeboten. NUR ...
 PR Newswire1 month ago

IMBRUVICA®▼(ibrutinib) de Janssen reçoit une autre approbation donnée par la Commission européenne pour le traitement de la macroglobulinémie…

 Gnom.es2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less